Bangalore, India, 560085
This combination tablet of Voglibose, Glimepiride, and Metformin HCL is designed for effective management of type 2 diabetes mellitus. Metformin HCL 1000 mg helps reduce hepatic glucose production and improves insulin sensitivity. Glimepiride 1 mg stimulates insulin release from pancreatic β-cells, helping lower blood sugar levels. Voglibose 0.1 mg, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestine, controlling postprandial hyperglycemia. Together, this triple therapy offers comprehensive glycemic control, improving fasting and post-meal blood glucose levels while minimizing the risk of complications associated with uncontrolled diabetes.